Xavier Durando

4.8k total citations
140 papers, 2.9k citations indexed

About

Xavier Durando is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xavier Durando has authored 140 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 46 papers in Cancer Research and 45 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xavier Durando's work include Breast Cancer Treatment Studies (35 papers), Cancer Treatment and Pharmacology (27 papers) and Glioma Diagnosis and Treatment (22 papers). Xavier Durando is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), Cancer Treatment and Pharmacology (27 papers) and Glioma Diagnosis and Treatment (22 papers). Xavier Durando collaborates with scholars based in France, Italy and United States. Xavier Durando's co-authors include P. Chollet, Catherine Abrial, Émilie Thivat, Marie‐Ange Mouret‐Reynier, E. Planchat, Frédérique Penault‐Llorca, Marianne Leheurteur, Pierre Gimbergues, Émilie Gadéa and Fabrice Kwiatkowski and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Xavier Durando

130 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xavier Durando France 31 1.0k 886 774 480 317 140 2.9k
Catherine Abrial France 22 772 0.7× 506 0.6× 722 0.9× 254 0.5× 341 1.1× 78 1.7k
Qinhong Xu China 36 1.2k 1.2× 1.7k 1.9× 974 1.3× 260 0.5× 142 0.4× 72 3.2k
Keiji Matsuda Japan 30 1.2k 1.2× 615 0.7× 488 0.6× 535 1.1× 359 1.1× 162 2.8k
Marie‐Ange Mouret‐Reynier France 22 796 0.8× 364 0.4× 704 0.9× 229 0.5× 279 0.9× 81 1.6k
Whitney A. Spannuth United States 25 741 0.7× 1.2k 1.4× 403 0.5× 230 0.5× 168 0.5× 33 2.5k
Shiu‐Ru Lin Taiwan 32 1.1k 1.1× 1.1k 1.2× 818 1.1× 485 1.0× 446 1.4× 105 2.7k
Émilie Thivat France 19 420 0.4× 401 0.5× 286 0.4× 184 0.4× 85 0.3× 60 1.2k
Joaquim Bosch‐Barrera Spain 30 1.1k 1.1× 1.4k 1.6× 563 0.7× 857 1.8× 148 0.5× 125 2.7k

Countries citing papers authored by Xavier Durando

Since Specialization
Citations

This map shows the geographic impact of Xavier Durando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Durando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Durando more than expected).

Fields of papers citing papers by Xavier Durando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Durando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Durando. The network helps show where Xavier Durando may publish in the future.

Co-authorship network of co-authors of Xavier Durando

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Durando. A scholar is included among the top collaborators of Xavier Durando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Durando. Xavier Durando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abrial, Catherine, et al.. (2025). Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review. Indian Journal of Gynecologic Oncology. 23(1). 1 indexed citations
2.
Biau, J., Xavier Durando, Ioana Molnar, et al.. (2024). NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution. Clinical and Translational Radiation Oncology. 48. 100833–100833. 14 indexed citations
3.
Robert, Caroline, Caroline Dutriaux, Felix Boakye Oppong, et al.. (2024). Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).. Journal of Clinical Oncology. 42(17_suppl). LBA9503–LBA9503. 3 indexed citations
4.
5.
Molnar, Ioana, et al.. (2023). RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire. BMC Cancer. 23(1). 679–679. 4 indexed citations
6.
Durando, Xavier, et al.. (2023). Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab. OncoTargets and Therapy. Volume 16. 359–369. 7 indexed citations
7.
8.
9.
Ginzac, Angeline, Ioana Molnar, Xavier Durando, et al.. (2021). Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC Cancer. 21(1). 864–864. 8 indexed citations
10.
Ginzac, Angeline, et al.. (2021). Sister Mary Joseph Nodules: A Case Report about a Rare Location of Skin Metastasis. Case Reports in Oncology. 14(1). 664–670. 6 indexed citations
11.
Ginzac, Angeline, Émilie Gadéa, Catherine Abrial, et al.. (2019). Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity. Oncology. 96(5). 223–234. 27 indexed citations
12.
Morel, Véronique, Dominique Joly, Claude Dubray, et al.. (2016). Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients. PLoS ONE. 11(4). e0152741–e0152741. 41 indexed citations
13.
Nohuz, E., et al.. (2016). Vaginal Lymphoma: A Possible Cause of Genital Hemorrhage. Turkish Journal of Hematology. 33(3). 259–260. 2 indexed citations
14.
Mahammedi, Hakim, E. Planchat, Xavier Durando, et al.. (2016). The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology. 90(2). 69–78. 112 indexed citations
15.
Chalabi, Nasséra, Catherine Abrial, Nina Radosevic‐Robin, et al.. (2015). Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology. 95(1). 88–104. 68 indexed citations
16.
Thivat, Émilie, Olivier Lapirot, Catherine Abrial, et al.. (2010). Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer. 10(1). 648–648. 92 indexed citations
17.
Gimbergues, Pierre, Catherine Abrial, Xavier Durando, et al.. (2008). Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation. Annals of Surgical Oncology. 15(5). 1316–1321. 68 indexed citations
18.
Penault‐Llorca, Frédérique, Catherine Abrial, Marie‐Ange Mouret‐Reynier, et al.. (2007). Achieving Higher Pathological Complete Response Rates in HER-2–Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast Cancer. The Oncologist. 12(4). 390–396. 7 indexed citations
19.
Chollet, P., Catherine Abrial, Marie‐Ange Mouret‐Reynier, et al.. (2006). Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer. Clinical Breast Cancer. 7(4). 336–338. 39 indexed citations
20.
Penault‐Llorca, Frédérique, Xavier Durando, & Jacques‐Olivier Bay. (2003). Valeur pronostique du récepteur du facteur de croissance épidermique.. Bulletin du Cancer. 90. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Abrial Breakdown of academic impact, for papers by Qinhong Xu Breakdown of academic impact, for papers by Keiji Matsuda Breakdown of academic impact, for papers by Marie‐Ange Mouret‐Reynier Breakdown of academic impact, for papers by Whitney A. Spannuth Breakdown of academic impact, for papers by Shiu‐Ru Lin Breakdown of academic impact, for papers by Émilie Thivat Breakdown of academic impact, for papers by Joaquim Bosch‐Barrera
Rankless by CCL
2026